AARD Company Profile and Key Details

AARD has shown sold momentum, gaining 4.58% over the past week and 21.16% over the past quarter, though year-to-date performance is up 18.25%. Short-term trend indicators are mixed aligned (SMA20 -0.86%, SMA50 -8.09%, SMA200 3.19%). The stock’s 14-day RSI is 45.42 (neutral), while the ATR of 0.8 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -30.32% below its high and over 156.15% above its low. Average 10-day trading volume of 453.45 thousand shares is significantly above the 3-month average of 221.23 thousand, indicating heightened recent market interest.

Aardvark Therapeutics, Inc. Common Stock has 21.77 million shares outstanding. The public float is 11.17 million shares, elevated short interest at 13.24% of float. This equals 1.88 million shares. The short ratio is 11.22 days. Institutional investors hold 62.23% of the float. Insiders own 14.55%. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Aardvark Therapeutics, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.71. This means the shares are trading above this model’s fair value.

Wall Street analysts project EPS growth of 10.05% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 10 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $50.00 to $18.00. The high target offers 814.08% upside. The low target suggests 229.07% downside. The mean target is $29.33. This offers 436.2% upside. Aardvark Therapeutics, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by -8.36%. The prior quarter beat by 26.92%. Over the last six quarters, Apple has recorded several small beats. These include 26.92% in August 13, 2025.

Our AI price prediction model suggests that Aardvark Therapeutics, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 112.61%, with price expected at $11.63 by March 13, 2026, within a range of $10.82 to $12.40 3-Month Outlook: Projected rise of 75.87%, reaching $9.62 by May 28, 2026, with a range of $9.20 to $10.01. 1-Year Outlook: Projected gain of 282.82%, with price at $20.94 by February 26, 2027, within a range of $20.62 to $21.18.

Aardvark Therapeutics, Inc. Common Stock (NASDAQ:AARD) shares are up 18.25% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Aardvark Therapeutics, Inc. Common Stock trading at a premium to the broader market with a P/E of -2.4. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $29.33, suggesting 436.2% upside. Our AI forecast model points to short-term strength (112.61% over two weeks), a medium-term rise (75.87% over three months), and a longer-term gain (282.82% over one year), with expected trading ranges indicating moderate volatility.

Aardvark Therapeutics, Inc. Common Stock (NASDAQ:AARD) closed at $5.47 USD, losing -$7.02 (-56.20%) from the previous close of $12.49. The stock is currently mid-range between its 52-week high and low $4.88 and $17.94. With a market capitalization of about $119.10 million, Aardvark Therapeutics, Inc. Common Stock is classified as a micro-cap and shows higher-than-market volatility (beta ~3.13). Key stats such as the average daily volume over the past year has been around 190.53 thousand shares, trading with heavier-than-usual volume. Headquartered in San Diego, CA, Aardvark Therapeutics, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Tien-Li Lee, the company employs approximately 22 people and listed since February 13, 2025. Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.

Aardvark Therapeutics, Inc. Common Stock trades at a P/E ratio of -2.4, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.96 suggesting the stock is closer to book value. The P/FCF stands at -2.46, also above market averages.